Induction of nitric oxide by erythropoietin is mediated by the β common receptor and requires interaction with VEGF receptor 2

Blood

Volumn 115, Issue 4, 2010, Pages 896-905

  Sautina, Larysa ^a   Sautin, Yuri ^a   Beem, Elaine ^a   Zhou, Zhuo ^b   Schuler, Anna ^a   Brennan, Jennafer ^a   Zharikov, Sergey I ^a   Diao, Yanpeng ^a   Bungert, Jorg ^b   Segal, Mark S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NITRIC OXIDE; VASCULOTROPIN RECEPTOR 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NOS3 PROTEIN, HUMAN; NOS3 PROTEIN, MOUSE; PROTEIN KINASE B; PROTEIN SUBUNIT; VASCULOTROPIN A;

ARTICLE; CELL COUNT; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ERYTHROPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STEM CELL; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DIMERIZATION; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MOUSE; MOUSE MUTANT; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; DIMERIZATION; ERYTHROPOIETIN; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR CROSS-TALK; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77949312123     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-216432     Document Type: Article

References (59)

1. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med. 1995;333(5):283-287.
2. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997. 1997;275(5302):964-966. (Pubitemid 27087709)
3. Llevadot J, Murasawa S, Kureishi Y, et al. HMGCoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108(3):399-405. (Pubitemid 32730786)
4. Ma FX, Chen F, Ren Q, Han ZC. Lovastatin restores the function of endothelial progenitor cells damaged by oxLDL. Acta Pharmacol Sin. 2009; 30(5):545-552.
5. Bahlmann FH, de Groot K, Spandau J-M, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103(3):921-926. (Pubitemid 38129551)
6. Lipsic E, van der Meer P, Voors A, et al. A Single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20(2):135-141. (Pubitemid 43876097)
7. Besler C, Doerries C, Giannotti G, Luscher TF, Landmesser U. Pharmacological approaches to improve endothelial repair mechanisms. Expert Rev Cardiovasc Ther. 2008;6(8):1071-1082.
8. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998; 101(11):2567-2578. (Pubitemid 28270451)
9. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells: protective effect of nitric oxide. Circ Res. 1997;81(6):970-976. (Pubitemid 27514946)
10. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9(11):1370-1376. (Pubitemid 37466185)
11. Aicher A, Heeschen C, Dimmeler S. The role of NOS3 in stem cell mobilization. Trends Mol Med. 2004;10(9):421-425. (Pubitemid 39209207)
12. Constantinescu SN, Keren T, Socolovsky M, Nam H-s Henis YI, Lodish HF. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A. 2001;98(8):4379-4384. (Pubitemid 32294985)
13. Mun KC, Golper TA. Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif. 2000;18(1):13-17.
14. Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist. 2004;10(2):93-98. (Pubitemid 38372870)
15. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305(5681):239-242.
16. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004; 101(41):14907-14912.
17. Shah R, Beem E, Sautina L, Zharikov SI, Segal MS. Mitomycin- and calcineurin-associated HUS, endothelial dysfunction and endothelial repair: a new paradigm for the puzzle? Nephrol Dial Transplant. 2007;22(2):617-620. (Pubitemid 46189910)
18. Segal MS, Beem E. Effect of pH, ionic charge, and osmolality on cytochrome c-mediated caspase-3 activity. Am J Physiol Cell Physiol. 2001;281(4):C1196-C1204. (Pubitemid 32948107)
19. Hill JM, Zalos G, Halcox JPJ, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348(7):593-600. (Pubitemid 36204953)
20. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9):2752-2760. (Pubitemid 39434958)
21. Case J, Mead LE, Bessler WK, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007; 35(7):1109-1118.
22. Prater DN, Case J, Ingram DA, Yoder MC. Working hypothesis to redefine endothelial progenitor cells. Leukemia. 2007;21(6):1141-1149. (Pubitemid 46831802)
23. Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2005;102(6): 2046-2051. (Pubitemid 40262009)
24. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A. 1977;74(8):3203-3207.
25. Katsuki S, Murad F. Regulation of adenosine cyclic 3′,5′- monophosphate and guanosine cyclic 3′,5′-monophosphate levels and contractility in bovine tracheal smooth muscle. Mol Pharmacol. 1977;13(2):330-341.
26. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res. 1977;3(1):23-35.
27. Wang L, Chopp M, Gregg SR, et al. Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF. J Cereb Blood Flow Metab. 2008;28(7):1361-1368.
28. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell. 1993; 74(2):227-236. (Pubitemid 23221699)
29. Feliers D, Chen X, Akis N, Choudhury GG, Madaio M, Kasinath BS. VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int. 2005;68(4):1648-1659. (Pubitemid 43169910)
30. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93(8):2627-2636. (Pubitemid 29181195)
31. Muller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RHG, Bloch W. Role of erythropoetin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am J Physiol Heart Circ Physiol. 2006;290(1):H331-H340.
32. Crosby JR, Kaminski WE, Schatteman G, et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res. 2000;87(9):728-730.
33. Paul JD, Powell TM, Thompson M, et al. Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac rehabilitation. J Cardiopulm Rehabil Prev. 2007;27(2):65-73. (Pubitemid 46673679)
34. Klingmüller U. The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells. Eur J Biochem. 1997;249(3): 637-647.
35. Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica. 1998;83(8):724-732.
36. Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction. Cell. 1991;64(2): 281-302.
37. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997;90(5): 1867-1873. (Pubitemid 27377296)
38. Blake TJ, Jenkins BJ, D'Andrea RJ, Gonda TJ. Functional cross-talk between cytokine receptors revealed by activating mutations in the extracellular domain of the beta-subunit of the GM-CSF receptor. J Leukoc Biol. 2002;72(6):1246-1255.
39. D'Andrea RJ, Gonda TJ. A model for assembly and activation of the GM-CSF, IL-3 and IL-5 receptors: insights from activated mutants of the common beta subunit. Exp Hematol. 2000;28(3): 231-243.
40. Scott CL, Robb L, Papaevangeliou B, Mansfield R, Nicola NA, Begley CG. Reassessment of interactions between hematopoietic receptors using common beta-chain and interleukin-3-specific receptor beta-chain-null cells: no evidence of functional interactions with receptors for erythropoietin, granulocyte colony-stimulating factor, or stem cell factor. Blood. 2000;96(4):1588-1590.
41. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal. 2007; 19(3):634-645. (Pubitemid 46107815)
42. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003; 102(4):1340-1346. (Pubitemid 36988041)
43. Bahlmann FH, Degroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003;64(5):1648-1652. (Pubitemid 37323692)
44. George J, Goldstein E, Abashidze A, et al. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res. 2005;68(2):299-306. (Pubitemid 41428426)
45. Hamed S, Barshack I, Luboshits G, et al. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J. 2006;27(15):1876-1883. (Pubitemid 44297396)
46. Prunier F, Pfister O, Hadri L, et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 2007;292(1):H522-H529. (Pubitemid 46105216)
47. Westenbrink BD, Lipsic E, van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007;28(16):2018-2027. (Pubitemid 47579534)
48. Anne MB, Adriaan AV, Wiek HvG, et al. Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J. 2008;155(5):817-822.
49. Shigematsu H, Iwasaki H, Otsuka T, Ohno Y, Arima F, Niho Y. Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity. J Biol Chem. 1997;272(22):14334- 14340. (Pubitemid 27232848)
50. Sivertsen EA, Hystad ME, Gutzkow KB, et al. PI3-K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells. Br J Haematol. 2006;135(1):117-128.
51. Min J-K, Han K-Y, Kim E-C, et al. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res. 2004;64(2):644-651. (Pubitemid 38120905)
52. Fieber CB, Eldridge J, Taha TA, Obeid LM, Muise-Helmericks RC. Modulation of total Akt kinase by increased expression of a single isoform: requirement of the sphingosine-1-phosphate receptor, Edg3/S1P3, for the VEGF-dependent expression of Akt3 in primary endothelial cells. Exp Cell Res. 2006;312(7):1164-1173.
53. Saulle E, Riccioni R, Coppola S, et al. Colocalization of the VEGF-R2 and the common Il-3/GMCSF receptor beta chain to lipid rafts leads to enhanced P38 activation. Br J Haematol. 2009; 145(3):399-411.
54. Mihov D, Vogel J, Gassmann M, Bogdanova A. Erythropoietin activates nitric oxide synthase in murine erythrocytes. Am J Physiol Cell Physiol. 2009;297(2):C378-C388.
55. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23(25):5960-5972.
56. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res. 1996;56(6):1324-1330. (Pubitemid 26084349)
57. Cudmore M,Ahmad S, Al-Ani B, Hewett P,Ahmed S, AhmedA. VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem Biophys Res Commun. 2006;345(4):1275-1282. (Pubitemid 43833439)
58. Ehara A, Takeda Y, Kida T, Mizukami S, Hagisawa M, Yamada Y. Time-course changes of eosinophil counts in premature infants: no effects of medical manipulation, except erythropoietin treatment, on eosinophilia. Pediatr Int. 2000; 42(1):58-60.
59. Jung YJ, Woo SY, Jang MH, et al. Human eosinophils show chemotaxis to lymphoid chemokines and exhibit antigen-presenting-cell-like properties on stimulation with IFN-γ, IL-3 and GM-CSF. Intl Arch Allergy Immunol. 2008; 146(3):227-234.